225
Participants
Start Date
September 25, 2023
Primary Completion Date
February 29, 2028
Study Completion Date
February 29, 2028
INCA033989
INCA033989 will be administered at protocol defined dose.
Ruxolitinib
Rux will be administered according to Prescribing Information/SmPC.
RECRUITING
Fondazione Irccs Ca Granda Ospedale Maggiore, Milan
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Chu Nimes, Nîmes
RECRUITING
Institut Bergonie, Bordeaux
RECRUITING
Aou Policlinico S. Orsola-Malpighi, Bologna
RECRUITING
Hospital Universitari I Politecnic La Fe, Valencia
RECRUITING
Azienda Ospedaliero-Universitaria Careggi (Aouc), Florence
RECRUITING
University Medical Center Rwth Aachen, Aachen
RECRUITING
Hospital Saint Louis, Paris
RECRUITING
Universitatsklinikum Ulm, Ulm
RECRUITING
Institut Gustave Roussy, Villejuif
RECRUITING
Royal Brisbane and Women'S Hospital, Herston
RECRUITING
Royal Adelaide Hospital, Adelaide
WITHDRAWN
Odense University Hospital, Odense C
RECRUITING
Peter Maccallum Cancer Centre, Melbourne
RECRUITING
The Alfred Hospital, Melbourne
RECRUITING
Princess Margaret Cancer Center, Toronto
RECRUITING
Hopital Maisonneuve-Rosemont, Montreal, Qc, Montreal
RECRUITING
Sjaellands Universitetshospital, Roskilde
RECRUITING
Vejle Hospital, Vejle
RECRUITING
Universitatsklinikum Halle (Saale), Halle
RECRUITING
National Cancer Center Hospital East, Chiba
RECRUITING
Kagoshima University Hospital, Kagoshima
RECRUITING
Osaka Metropolitan University Hospital, Osaka
RECRUITING
Nippon Medical School Hospital, Tokyo
RECRUITING
Mie University Hospital, Tsu
RECRUITING
Guys and St Thomas Nhs Foundation Trust, London
RECRUITING
The Christie Nhs Foundation Trust Uk, Manchester
RECRUITING
University of Oxford, Oxford
Lead Sponsor
Incyte Corporation
INDUSTRY